• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Intrathecal tofersen for amyotrophic lateral sclerosis

byConstance Wu
August 28, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A 100mg treatment of tofersen was shown to decrease cerebrospinal fluid (CSF) superoxide dismutase 1 (SOD1) concentration in adults with amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.

2. Lumbar puncture-related adverse events were shown to be present in most participants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Amyotrophic lateral sclerosis, resulting from superoxide dismutase 1 (SOD1) mutations consist of approximately 2% of all cases with over 180 disease-causing mutations identified within the gene. Tofersen is an antisense oligonucleotide (ASO) which mediates SOD1 mRNA degradation, thereby, reducing the synthesis of SOD1 protein. However, the effect of tofersen dosing on patients diagnosed with ALS is unknown. As such, this study evaluated the safety, pharmacokinetics, and pharmacodynamics of tofersen in adults with SOD1 mutation mediated ALS. Intrathecal administration of tofersen was shown to significant reduce CSF SOD1 concentrations. While, this study was adequately powered to test the reduction of SOD1 concentration in the CSF, the study was not able to conclusively determine other clinical or biological measures due to its low power. Nonetheless, this study was strengthened by its extensive follow-up period and the additional analyses conducted on the exploratory nature of the efficacy outcomes.

Click to read the study, published today in NEJM

Relevant reading: Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

In-Depth [randomized controlled trial]: This randomized control trial enrolled 50 patients across 18 sites in the United States, Canada, and Western Europe. Patients enrolled in the study were adults over the age of 18 years with muscle weakness attributed to ALS, documented SOD1 mutation, and normal coagulation variables. The exclusion criteria for the study included participants currently taking or scheduled to start edaravone treatment. Patients were randomized in a 3:1 ratio to receive 20, 40, 60, or 100 mg tofersen doses or a placebo regimen. A single dose of the treatment was administered on days 1, 15, 29, 57, and 85. The primary outcome was treatment safety. The most common adverse events included headache (16 participants, 32%), procedural pain (16 participants, 32%), and post-lumbar puncture syndrome (13 participants, 26%). The difference in ratio of CSF SOD1 concentration between baseline and day 85 for the 20-mg group was 2 percentage points (95% confidence interval [CI], -18 to 27) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 40-mg group was -25 percentage points (95% CI, -40 to -5) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 60-mg group was -19 percentage points (95% CI, -35 to 2) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 100-mg group was -33 percentage points (95% CI, -47 to -16) compared to the placebo group. Taken together, the 100-mg tofersen treatment was shown to decrease SOD1 concentration in adults with ALS with associated procedural-related adverse events.

RELATED REPORTS

Variants in the SPTLC1 gene associated with juvenile amyotrophic lateral sclerosis

Ezogabine with potential to slow disease progression for amyotrophic lateral sclerosis in phase 2 trial

2 Minute Medicine Rewind November 30, 2020

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ALSamyotrophic lateral sclerosisamyotrophic lateral sclerosis (ALS)tofersen
Previous Post

Better glucose control with closed-loop system in children with type 1 diabetes

Next Post

2 Minute Medicine Rewind August 31, 2020

RelatedReports

Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Chronic Disease

Variants in the SPTLC1 gene associated with juvenile amyotrophic lateral sclerosis

September 3, 2021
Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Neurology

Ezogabine with potential to slow disease progression for amyotrophic lateral sclerosis in phase 2 trial

December 1, 2020
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind November 30, 2020

November 30, 2020
#VisualAbstract: Sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis patients
StudyGraphics

#VisualAbstract: Sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis patients

October 13, 2020
Next Post
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

2 Minute Medicine Rewind August 31, 2020

Quick Take: Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children

Internet searches related to acute anxiety rose significantly following declaration of COVID-19 as a national emergency in the US

Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.